Compare · SNN vs ZJYL
SNN vs ZJYL
Side-by-side comparison of Smith & Nephew SNATS Inc. (SNN) and JIN MEDICAL INTERNATIONAL LTD. (ZJYL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SNN and ZJYL operate in Industrial Specialties (Health Care), so they compete in similar markets.
- SNN is the larger of the two at $12.18B, about 35.7x ZJYL ($340.9M).
- Over the past year, SNN is down 20.0% and ZJYL is down 67.9% - SNN leads by 47.9 points.
- SNN has hit the wire 7 times in the past 4 weeks while ZJYL has been quiet.
- SNN has more recent analyst coverage (25 ratings vs 0 for ZJYL).
- Company
- Smith & Nephew SNATS Inc.
- JIN MEDICAL INTERNATIONAL LTD.
- Price
- $29.06-0.07%
- $2.19+5.54%
- Market cap
- $12.18B
- $340.9M
- 1M return
- +4.57%
- +6.05%
- 1Y return
- -19.99%
- -67.87%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 0
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Latest SNN
- SEC Form S-8 filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal
- Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
- Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
- Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
- Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System
Latest ZJYL
- SEC Form 6-K filed by JIN MEDICAL INTERNATIONAL LTD.
- SEC Form 6-K filed by JIN MEDICAL INTERNATIONAL LTD.
- SEC Form 6-K filed by JIN MEDICAL INTERNATIONAL LTD.
- JIN MEDICAL INTERNATIONAL LTD. Reports First Half of Fiscal Year 2026 Financial Results
- SEC Form 6-K filed by JIN MEDICAL INTERNATIONAL LTD.
- SEC Form 3 filed by new insider Xue Ning
- SEC Form 6-K filed by JIN MEDICAL INTERNATIONAL LTD.
- Amendment: SEC Form 6-K/A filed by JIN MEDICAL INTERNATIONAL LTD.
- SEC Form 6-K filed by JIN MEDICAL INTERNATIONAL LTD.
- SEC Form 6-K filed by JIN MEDICAL INTERNATIONAL LTD.